Payment overview · 2025
General Payments
$451.42
25 reported records · 14 companies
Healthcare provider profile · identity verified
Thomas James Jackson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SULLIVAN, MO · NPI 1528262698
Verified facts
What the public records show
CMS Open Payments records show Thomas James Jackson, M.D. received $451.42 in general payments during 2025 across 25 reported records.
ABBVIE INC. accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Mounjaro, Ozempic, Qulipta, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 302 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 322 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Rexulti by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.08 | 31.0% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $77.08 | 17.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.94 | 9.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.14 | 5.1% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $21.65 | 4.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.41 | 4.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.33 | 4.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.44 | 4.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.62 | 3.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.50 | 3.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.22 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.11 | 3.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.75 | 3.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.15 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $374.34 | 23 |
| Education | $77.08 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $120.02 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $97.73 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $42.35 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.11 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 47 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 190 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 293 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 85 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 302 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
72 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
76 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
47 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
302 | 61 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
147 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
322 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
190 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
93 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
293 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
85 | 15 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1550 | 329 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1276 | 219 |
| Gabapentin | Gabapentin | 1267 | 216 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1042 | 195 |
| Lisinopril | Lisinopril | 1033 | 227 |
| Amlodipine Besylate | Amlodipine Besylate | 946 | 204 |
| Furosemide | Furosemide | 926 | 173 |
| Duloxetine Hcl | Duloxetine Hcl | 911 | 192 |
| Eliquis | Apixaban | 896 | 109 |
| Omeprazole | Omeprazole | 841 | 181 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 785 | 109 |
| Alprazolam | Alprazolam | 758 | 116 |
| Oxycodone Hcl | Oxycodone Hcl | 757 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 716 | 140 |
| Metoprolol Tartrate | Metoprolol Tartrate | 632 | 110 |
| Potassium Chloride | Potassium Chloride | 617 | 98 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 601 | 144 |
| Metformin Hcl | Metformin Hcl | 533 | 114 |
| Trazodone Hcl | Trazodone Hcl | 518 | 104 |
| Montelukast Sodium | Montelukast Sodium | 493 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 493 | 101 |
| Tramadol Hcl | Tramadol Hcl | 471 | 123 |
| Baclofen | Baclofen | 460 | 116 |
| Prednisone | Prednisone | 458 | 238 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 445 | 83 |
| Losartan Potassium | Losartan Potassium | 424 | 84 |
| Lorazepam | Lorazepam | 402 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 391 | 71 |
| Sertraline Hcl | Sertraline Hcl | 367 | 59 |
| Carvedilol | Carvedilol | 363 | 73 |
| Amitriptyline Hcl | Amitriptyline Hcl | 354 | 80 |
| Metoprolol Succinate | Metoprolol Succinate | 337 | 81 |
| Jardiance | Empagliflozin | 322 | 49 |
| Azithromycin | Azithromycin | 315 | 206 |
| Buspirone Hcl | Buspirone Hcl | 313 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 305 | 69 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 302 | 66 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 302 | 61 |
| Mirtazapine | Mirtazapine | 293 | 64 |
| Ozempic | Semaglutide | 293 | 47 |
| Simvastatin | Simvastatin | 291 | 59 |
| Famotidine | Famotidine | 268 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 263 | 49 |
| Pregabalin | Pregabalin | 247 | 51 |
| Myrbetriq | Mirabegron | 241 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 237 | 88 |
| Spironolactone | Spironolactone | 237 | 44 |
| Levetiracetam | Levetiracetam | 220 | 39 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 218 | 48 |
| Topiramate | Topiramate | 216 | 48 |
| Finasteride | Finasteride | 211 | 35 |
| Ropinirole Hcl | Ropinirole Hcl | 211 | 43 |
| Doxycycline Hyclate | Doxycycline Hyclate | 201 | 139 |
| Ondansetron Hcl | Ondansetron Hcl | 199 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 197 | 32 |
| Meloxicam | Meloxicam | 197 | 48 |
| Glipizide | Glipizide | 192 | 44 |
| Clonazepam | Clonazepam | 191 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 191 | 47 |
| Allopurinol | Allopurinol | 190 | 46 |
| Mounjaro | Tirzepatide | 190 | 39 |
| Risperidone | Risperidone | 181 | 28 |
| Aripiprazole | Aripiprazole | 173 | 37 |
| Olanzapine | Olanzapine | 173 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 165 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 163 | 33 |
| Ezetimibe | Ezetimibe | 148 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 148 | 27 |
| Xarelto | Rivaroxaban | 147 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 34 |
| Celecoxib | Celecoxib | 140 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 140 | 34 |
| Alendronate Sodium | Alendronate Sodium | 139 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 134 | 99 |
| Fluoxetine Hcl | Fluoxetine Hcl | 134 | 27 |
| Propranolol Hcl | Propranolol Hcl | 134 | 30 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 131 | 84 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 28 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 125 | 15 |
| Clonidine Hcl | Clonidine Hcl | 124 | 23 |
| Metformin Hcl Er | Metformin Hcl | 123 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 28 |
| Dicyclomine Hcl | Dicyclomine Hcl | 119 | 21 |
| Atenolol | Atenolol | 116 | 22 |
| Bumetanide | Bumetanide | 116 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 113 | 87 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 108 | 19 |
| Warfarin Sodium | Warfarin Sodium | 105 | 14 |
| Glimepiride | Glimepiride | 102 | 26 |
| Donepezil Hcl | Donepezil Hcl | 101 | 22 |
| Lovastatin | Lovastatin | 101 | 20 |
| Metoclopramide Hcl | Metoclopramide Hcl | 101 | 17 |
| Movantik | Naloxegol Oxalate | 101 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 100 | 20 |
| Diazepam | Diazepam | 100 | 28 |
| Memantine Hcl | Memantine Hcl | 99 | 16 |
| Ondansetron Odt | Ondansetron | 97 | 57 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 95 | 13 |
| Entresto | Sacubitril/Valsartan | 93 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 93 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 93 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 90 | 18 |
| Levofloxacin | Levofloxacin | 87 | 50 |
| Bupropion Hcl Sr | Bupropion Hcl | 85 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 85 | 15 |
| Rexulti | Brexpiprazole | 85 | 15 |
| Nystatin | Nystatin | 83 | 49 |
| Cefdinir | Cefdinir | 80 | 49 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 79 | 18 |
| Ibuprofen | Ibuprofen | 78 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 77 | 17 |
| Latanoprost | Latanoprost | 77 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 76 | 19 |
| Bupropion Xl | Bupropion Hcl | 75 | 19 |
| Enalapril Maleate | Enalapril Maleate | 75 | 11 |
| Terazosin Hcl | Terazosin Hcl | 75 | 21 |
| Primidone | Primidone | 73 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 72 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 72 | 26 |
| Januvia | Sitagliptin Phosphate | 72 | 11 |
| Synthroid | Levothyroxine Sodium | 72 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 71 | 14 |
| Glipizide Er | Glipizide | 68 | 17 |
| Methotrexate | Methotrexate Sodium | 67 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 65 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 65 | 11 |
| Linzess | Linaclotide | 64 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 64 | 13 |
| Cephalexin | Cephalexin | 63 | 43 |
| Farxiga | Dapagliflozin Propanediol | 61 | 12 |
| Methocarbamol | Methocarbamol | 61 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 61 | 17 |
| Promethazine Hcl | Promethazine Hcl | 60 | suppressed |
| Sucralfate | Sucralfate | 60 | 12 |
| Nitroglycerin | Nitroglycerin | 59 | 32 |
| Azelastine Hcl | Azelastine Hcl | 57 | 22 |
| Meclizine Hcl | Meclizine Hcl | 57 | 18 |
| Midodrine Hcl | Midodrine Hcl | 57 | 15 |
| Valsartan | Valsartan | 57 | suppressed |
| Folic Acid | Folic Acid | 56 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 56 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 12 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 54 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Trulicity | Dulaglutide | 53 | suppressed |
| Verapamil Er | Verapamil Hcl | 53 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 52 | 31 |
| Fluconazole | Fluconazole | 50 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 49 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 49 | 24 |
| Lamotrigine | Lamotrigine | 48 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 48 | 29 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 47 | 46 |
| Torsemide | Torsemide | 47 | 16 |
| Novolog Flexpen | Insulin Aspart | 46 | 15 |
| Nurtec Odt | Rimegepant Sulfate | 46 | suppressed |
| Estradiol | Estradiol | 44 | 11 |
| Methimazole | Methimazole | 44 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 43 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 42 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 41 | 12 |
| Bupropion Hcl | Bupropion Hcl | 41 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 41 | suppressed |
| Ketoconazole | Ketoconazole | 41 | 12 |
| Lithium Carbonate | Lithium Carbonate | 41 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 40 | 11 |
| Fentanyl | Fentanyl | 39 | suppressed |
| Loperamide | Loperamide Hcl | 39 | 15 |
| Roflumilast | Roflumilast | 39 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Tradjenta | Linagliptin | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Carisoprodol | Carisoprodol | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 25 |
| Spiriva Respimat | Tiotropium Bromide | 37 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 36 | suppressed |
| Gemtesa | Vibegron | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 19 |
| Calcitriol | Calcitriol | 34 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 33 | 33 |
| Dilt-Xr | Diltiazem Hcl | 32 | suppressed |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Methadone Hcl | Methadone Hcl | 31 | suppressed |
| Creon | Lipase/Protease/Amylase | 30 | suppressed |
| Metronidazole | Metronidazole | 30 | 17 |
| Naloxone Hcl | Naloxone Hcl | 30 | 29 |
| Naproxen | Naproxen | 30 | suppressed |
| Restasis | Cyclosporine | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 30 | 11 |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Metolazone | Metolazone | 29 | suppressed |
| Nyamyc | Nystatin | 29 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Qulipta | Atogepant | 27 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 27 | 18 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 26 | 14 |
| Amoxicillin | Amoxicillin | 25 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Humalog | Insulin Lispro | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Lubiprostone | Lubiprostone | 25 | suppressed |
| Misoprostol | Misoprostol | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 25 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Insulin Lispro | Insulin Lispro | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Lactulose | Lactulose | 22 | 11 |
| Minocycline Hcl | Minocycline Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Nystop | Nystatin | 21 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 20 | suppressed |
| Gvoke Hypopen 2-Pack | Glucagon | 20 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Valproic Acid | Valproic Acid | 20 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Azathioprine | Azathioprine | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Sulfasalazine | Sulfasalazine | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Enbrel Sureclick | Etanercept | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Epinephrine | Epinephrine | 16 | 14 |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | 13 |
| Rybelsus | Semaglutide | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxycontin | Oxycodone Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Travoprost | Travoprost | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Acetazolamide Er | Acetazolamide | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Easy-Touch Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 12 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Risperidone Odt | Risperidone | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Cyclosporine | Cyclosporine | 11 | suppressed |
| Daptomycin | Daptomycin | 11 | suppressed |
| Desvenlafaxine Er | Desvenlafaxine | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $451.42 · 25 records | ABBVIE INC. | AIRSUPRA, AREXVY, Auvelity, Cologuard Collection Kit, EVENITY, LEQVIO, MOUNJARO, Ozempic, PROLIA, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TREMFYA, TZIELD, VOQUEZNA, VRAYLAR, ZEPBOUND | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error